We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

BRUKER

BRUKER offers high-performance scientific instruments and high-value analytical and diagnostic solutions that enable ... read more Featured Products: More products

Download Mobile App




Cutaneous Leishmaniasis Species Identified by Mass Spectrometry

By LabMedica International staff writers
Posted on 18 Jun 2014
Print article
Image: The BrukerAutoflex MALDI-TOF mass spectrometer (Photo courtesy of Bruker-Daltonics).
Image: The BrukerAutoflex MALDI-TOF mass spectrometer (Photo courtesy of Bruker-Daltonics).
Image: Cutaneous Leishmaniasis lesion on the hand (Photo courtesy of D.S. Martin).
Image: Cutaneous Leishmaniasis lesion on the hand (Photo courtesy of D.S. Martin).
Cutaneous leishmaniasis (CL) is caused by several Leishmania species that are associated with variable outcomes before and after therapy and optimal treatment decision is based on an accurate identification of the infecting species.

Current methods to type Leishmania isolates are relatively complex and slow and therefore, the initial treatment decision is generally presumptive, the infecting species being suspected on epidemiological and clinical grounds. A simple method to type cultured isolates would facilitate disease management.

Scientists at the University Pierre et Marie Curie (Paris, France) performed parasitological diagnosis and analysis by lesion scraping, biopsy or aspirate followed by direct examination of Giemsa-stained smears, histological analysis, Giemsa-stained tissue sections, culture or polymerase chain reaction (PCR). They also analyzed promastigote pellets from 46 strains cultured in monophasic medium, including 20 short-term cultured isolates from French travelers, 19 with CL, and one with visceral leishmaniasis and clinical isolates were analyzed in parallel with Multilocus Sequence Typing (MLST).

The promastigote pellets were analyzed by Matrix Assisted Laser Desorption Ionization Time-of-Flight (MALDI-TOF) technology and performed on a BrukerAutoflex I MALDI-TOF mass spectrometer (Bruker-Daltonics, Bremen, Germany). Automatic dendrogram analysis generated a classification of isolates consistent with reference determination of species based on MLST or 70 kDa heat shock protein gene (hsp70) sequencing. An analysis of the spectra, based on a very simple, database-independent analysis of spectra, showed that the mutually exclusive presence of two pairs of peaks discriminated isolates considered by reference methods to belong either to the Viannia or Leishmania subgenus, and that within each subgenus presence or absence of a few peaks allowed discrimination to species complexes level.

The authors concluded that analysis of cultured Leishmania isolates using mass spectrometry allows a rapid and simple classification to the species complex level consistent with reference methods, a potentially useful method to guide treatment decision in patients with cutaneous leishmaniasis. The intuitive interpretation of spectra was well-suited for allowing for close interactions between parasitologists and clinicians. The study was published on June 5, 2014, in the journal Public Library of Science Neglected Tropical Diseases.

Related Links:

University Pierre et Marie Curie
Bruker-Daltonics


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Respiratory Bacterial Panel
Real Respiratory Bacterial Panel 2
New
H.pylori Test
Humasis H.pylori Card

Print article

Channels

Molecular Diagnostics

view channel
Image: Researcher Kanta Horie places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids (Photo courtesy of WashU Medicine)

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.